What is Agios Pharmaceuticals's cumulative cost basis?

Agios Pharmaceuticals (AGIO) reported cumulative cost basis of $932.21M in Q1 2026.

How has Agios Pharmaceuticals's cumulative cost basis changed year-over-year?

Agios Pharmaceuticals's cumulative cost basis decreased by 30.7% year-over-year, from $1.35B to $932.21M.

What is the long-term trend for Agios Pharmaceuticals's cumulative cost basis?

Over 5 years (2020 to 2025), Agios Pharmaceuticals's cumulative cost basis has grown at a 14.6% compound annual growth rate (CAGR), from $543M to $1.07B.

Agios Pharmaceuticals AGIO Cumulative Cost Basis

Cumulative Cost Basis at other companies

Vertex PharmaceuticalsVRTX

——

IncyteINCY

——

BioMarin PharmaceuticalsBMRN

——

PrecigenPGEN

——

Aurinia PharmaceuticalsAUPH

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.16B+18.1%

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's cumulative cost basis?: Agios Pharmaceuticals (AGIO) reported cumulative cost basis of $932.21M in Q1 2026.
How has Agios Pharmaceuticals's cumulative cost basis changed year-over-year?: Agios Pharmaceuticals's cumulative cost basis decreased by 30.7% year-over-year, from $1.35B to $932.21M.
What is the long-term trend for Agios Pharmaceuticals's cumulative cost basis?: Over 5 years (2020 to 2025), Agios Pharmaceuticals's cumulative cost basis has grown at a 14.6% compound annual growth rate (CAGR), from $543M to $1.07B.